In 2023, the re-import value of antisera and other blood fractions to China stood at 1.55 million USD. The forecasted growth presents a steady upward trend: rising to 1.611 million USD in 2024, and reaching 1.8486 million USD by 2028. The annual growth rate from 2024 onwards shows a modest increase, with a compound annual growth rate (CAGR) over the five-year period. This reflects the strengthening demand and reliance on biopharmaceutical imports.

Future trends to watch for include:

Increased domestic production capabilities, potentially affecting demand.
Global regulatory and trade policies impacting re-import volumes.
Technological advancements in synthetic alternatives that may alter market dynamics.